Analysis of immune responses induced by whole killed SIV with various adjuvants.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Analysis of immune responses induced by whole killed SIV with various adjuvants.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 62. Unique Identifier : AIDSLINE PRIM11/94191658
Ohkawa S; Wilson LA; Yamamoto F; Kiyono H; Martin L; Murphey-Corb M; Tulane Regional Primate Res. Center, Covington, LA 70433.

Abstract: Cellular and humoral immune responses were assessed in monkeys immunized with killed SIV virus alone or combined with different adjuvants. Adjuvant groups included no adjuvant (I), SAF-M (II), Freund's complete (III), alum (IV), detoxified lipid A (V), Freund's incomplete + MDP (VI), MTP-PE (VII), liposomes (VIII), lipid A in liposomes+alum (IX), and synthetic copolymer + detoxified LPS (X). Adjuvant X induced the greatest antibody responses to gp140; adjuvants II, III, IV, V, VI, and VII induced moderate responses; and the liposome adjuvants VIII and IX induced the least antibody. T-cell proliferative responses were assessed against uv-inactivated SIV, glycoprotein depleted SIV (gag), and recombinant glycoprotein (rGP140). Immunizations were given every 8 weeks, and the proliferative responses were assessed 5 weeks after the 2nd vaccination. Adjuvants II, III, IV, and VIII induced good proliferative responses to uv-SIV, gag, and rGP140. Adjuvant IX induced mild responses to rGP140 but poor responses to SIV and gag. Adjuvant X induced good responses to uv-SIV and gag but poor response to rGP140. Adjuvants III and VIII also induced good responses to synthetic peptides. Class-I restricted CTL responses were induced in vaccinates receiving adjuvants VII, VIII, or IX. In vitro stimulated PBMC produced IL-6 after immunization with adjuvants II, III, IV and VI; and in vitro IL-2 receptor production was significant after adjuvants II, III, IV, VIII, IX, and X. The spectrum of immune responses elicited by these different adjuvants, coupled with the outcome of challenge studies, should provide information vital to our understanding of immune responses which protect against SIV infection and/or disease.

Keywords: Adjuvants, Immunologic Animal Antibody Formation Comparative Study Haplorhini Immunity, Cellular Immunization Schedule Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/*IMMUNOLOGY Vaccines, Inactivated/*IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY ABSTRACT
940730
M9470860

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .